Last updated: April 24, 2026
Who Supplies Methohexital Sodium to the Pharmaceutical Supply Chain?
Methohexital sodium is an established, controlled anesthetic active pharmaceutical ingredient (API). In practice, supply is fragmented across (1) API manufacturers, (2) sterile injectable CDMO partners, and (3) specialty distributors that source from multiple upstream plants. Without named supplier data tied to your exact target (API vs finished injectable; country of supply; regulatory status; and whether you need GxP release), a complete, accurate “supplier list” cannot be produced.
Can a Complete, Verifiable Supplier List Be Provided From Patent-Grade Sources?
No. A patent-grade supplier rollup requires supplier names linked to verifiable documentation (for example: regulatory submissions, marketing authorizations, drug master files tied to named firms, or confirmed commercial listings). A general market description cannot yield an accurate list of specific suppliers for methohexital sodium.
What Supplier Categories Exist for Methohexital Sodium?
Even without naming specific firms, the supply chain for methohexital sodium typically breaks into these operational buckets:
- API manufacturers producing methohexital sodium in bulk (typically under GMP).
- Sterile injectable manufacturers or CDMOs compounding and finishing methohexital sodium into injectable presentation formats (where applicable).
- Authorized distributors sourcing API and finished product and managing distribution controls.
What Constraints Drive Supplier Selection for Methohexital Sodium?
Operational qualification for methohexital sodium usually focuses on:
- Regulatory controlled-substance handling (procurement controls, recordkeeping, and distribution licensing).
- GMP status and batch traceability for API or sterile finished product.
- Documentation completeness for regulatory filings (CoA, impurity profile, residual solvents if relevant, and stability program coverage).
What Can Be Done Reliably Without Supplier Names?
A business-plausible path is mapping methohexital sodium supply through buyer qualification logic rather than asserting names. That qualification logic drives procurement outcomes and reduces counterparty risk:
- Determine whether procurement target is API or finished sterile injectable.
- Confirm controlled-substance distribution eligibility in the destination market.
- Qualify for GMP release and provide full batch documentation.
- Verify stereochemistry, salt form, and spec conformance (methohexital sodium versus related barbiturate salts).
- Assess analytical capability for impurity and identity verification aligned to buyer standards.
Key Takeaways
- A complete, accurate list of suppliers for methohexital sodium cannot be produced from patent-grade verifiable sources without specifying the procurement target and confirmed supplier documentation.
- Supplier sourcing is split across API manufacture, sterile injectable finishing/CDMO, and specialty distribution, with controlled-substance controls and GMP traceability as primary filters.
- Procurement should be driven by qualification and documentation requirements rather than assumptions about upstream availability.
FAQs
1) Is the supplier list different for API versus finished injectable methohexital sodium?
Yes. API suppliers and sterile injectable manufacturers are often different entities.
2) Why do controlled-substance rules affect sourcing?
They add licensing, ordering controls, recordkeeping, and distribution restrictions that limit eligible distributors.
3) What documentation typically matters for qualification?
GMP evidence, CoA, batch traceability, impurity/identity methods, and stability support relevant to the dosage form.
4) What role do CDMOs play?
CDMOs often handle formulation, aseptic processing, filling, and packaging for sterile injectables sourced from upstream APIs.
5) Can generic market listings substitute for verified supplier data?
No. Generic listings lack the regulatory and traceability linkage needed for a procurement-grade supplier determination.
References
[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Methohexital Sodium (information if available for the specific product name and dosage form). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances regulations and registrant requirements. https://www.deadiversion.usdoj.gov/
[3] EMA. (n.d.). European public assessment reports and product information for relevant methohexital sodium medicinal products (if available). https://www.ema.europa.eu/
[4] World Health Organization. (n.d.). WHO guidelines and technical resources relevant to GMP and pharmaceutical quality systems. https://www.who.int/health-topics/drugs-and-therapeutics
